Literature DB >> 22193400

Therapeutics: Opening the door to a new class of proteasome inhibitors.

Alexandra Flemming1.   

Abstract

Year:  2011        PMID： 22193400     DOI： 10.1038/nrc3203

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN： 1474-175X            Impact factor:   60.716


× No keyword cloud information.
  1 in total

1.  Inhibition of proteasome deubiquitinating activity as a new cancer therapy.

Authors:  Pádraig D'Arcy; Slavica Brnjic; Maria Hägg Olofsson; Mårten Fryknäs; Kristina Lindsten; Michelandrea De Cesare; Paola Perego; Behnam Sadeghi; Moustapha Hassan; Rolf Larsson; Stig Linder
Journal:  Nat Med       Date:  2011-11-06       Impact factor: 53.440
  1 in total
  1 in total

1.  Proteasome inhibitor MG132 inhibits the proliferation and promotes the cisplatin-induced apoptosis of human esophageal squamous cell carcinoma cells.

Authors:  Lifeng Dang; Fengbiao Wen; Yang Yang; Donglei Liu; Kai Wu; Yu Qi; Xiangnan Li; Jia Zhao; Dengyan Zhu; Chunyang Zhang; Song Zhao
Journal:  Int J Mol Med       Date:  2014-02-27       Impact factor: 4.101
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.